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Highlight Text Box
Highlights
	AYA patients have a great diversity of different ovarian cancer histologies, ranging from germ cell tumors in adolescents to the predominance of epithelial tumors through young adulthood. Between ages 25-30 years germ cell tumors predominate, while  >90% are epithelial tumors in women older than 30 years of age. 
	The staging systems vary greatly for pediatric and adult patients and impacts on their treatment. This becomes acutely important in epithelial tumors where extensive and detailed surgery may be necessary.
	Access to care is a potential barrier, especially understanding who would be the most appropriate specialist. Pediatric surgeons and oncologists and gynecologic and medical oncologists participate in their care. 
	Hereditary genetic mutations are identified in approximately 20% women with ovarian cancer. Access to appropriate genetic counselling should is essential.
	Germline mutations such as DICER1 and SMARC4A have been shown to have increased incidence of ovarian tumors in AYA patients.
	Fertility issues are important to many patients. In a review of providers of care to adolescent cancer patients, 46% referred males but only 12% referred females to fertility specialists prior to starting chemotherapy. 
	Early menopause is also a complication of the treatment of AYA patients with ovarian tumors, especially adult histologies which require aggressive surgery.
	Historically, very few patients with ovarian cancer have been enrolled on clinical trials. There needs to be more co-ordination and communication between specialists who provide this care.











Ovarian Cancer in Adolescents and Young Adults

Introduction
Ovarian cancers account for 4% of female cancers ADDIN EN.CITE 1, becoming more common with increasing age. Incidence peaks between age 65 and 692 (Fig.1). Although ovarian cancers are rare in adolescents and young adults (AYA; defined here as 15-39 year olds), the spectrum of histologies is vastly different in this age group. Between 15 and 20 years, germ cell tumors account for 50% invasive cancers, while over 90% are epithelial for those aged 30 and older (Fig.2). In contrast to other malignancies affecting young people, the effect of these cancers and their treatment on female reproductive health strongly influences oncological management. 
	
Adolescents and young adults have the best 10 year ovarian cancer survival rates at over 85% compared to 35% overall3 (Fig.3). This may reflect more favorable histologies in AYA patients or the tendency of these histologies to present with lower stage disease (Fig.4). Evaluation of this relationship is complicated by different staging systems used in pediatric and adult practice (Supplementary Figure S1).  Progress in understanding how best to treat AYAs has been slow ADDIN EN.CITE 4, and few adolescent ovarian cancer patients have been enrolled in clinical trials to date ADDIN EN.CITE 5,6.

This review will discuss the management of different ovarian cancers in 15-39 year olds and highlight specific considerations in this unique patient subgroup.

Pathology (Fig.5A and Fig.5B)
A diverse range of malignancies occur in the ovary and are divided into epithelial cancers, germ cell tumors, sex cord stromal tumors and small cell carcinomas. Different histologies have distinct clinical behaviors and increasingly, different therapeutic options. Incidence, treatment and outcome vary markedly with patient age.

1. EPITHELIAL CARCINOMAS
Epithelial carcinomas are the most common subtype, accounting for approximately 90% of ovarian malignancies ADDIN EN.CITE 7. They are predominantly diseases of adult life and below age 20, they occur at a rate of < 1/100,000 population per year2. Epithelial ovarian cancers are divided into two distinct groups: Type I and the more common Type II.

1.2 Type II
Type II cancers are the most common subtype accounting for approximately 70% ovarian cancers ADDIN EN.CITE 7,8. The proportion is lower in Asia (56.1%), owing to their higher incidence of Type I cancers ADDIN EN.CITE 7. Type II tumors are biologically more aggressive than Type I. This group is dominated by the most common histological ovarian cancer subtype, High Grade Serous Carcinoma (HGSC). 

1.2.1 High Grade Serous Carcinoma
HGSC arise from serous tubal intraepithelial carcinomas (STICs) in the fallopian tube ADDIN EN.CITE 9. The defining genetic feature is mutation of TP53 ADDIN EN.CITE 10. Defects in homologous recombination repair pathways occur in at least 50% with germline mutations in BRCA1/2 in 12% and somatic BRCA1/2 mutations in a further 6%11. In a study of 5066 female BRCA mutation carriers (median age 38 years), the cumulative ovarian cancer risk to age 80 years was 44% for BRCA1 and 17% for BRCA2. Risk increased with age but was low up to age 40 for BRCA1 and age 50 for BRCA2 ADDIN EN.CITE 12. There is currently no effective screening program and so risk-reducing surgery is currently advised, usually in the 4th decade. More than 75% patients present with disease that has spread beyond the pelvis, most commonly with peritoneal and omental infiltration, large volume ascites and secretion of Ca125. Despite aggressive surgery and chemotherapy, most women are not cured of their disease and Type II tumors cause more than 90% of ovarian cancer deaths13. 

1.1. Type I 
Type I tumors account for 20% of ovarian cancers8. Their incidence is higher in Asian populations, where they account for over 30% of ovarian malignancies ADDIN EN.CITE 7. Type I cancers usually present as cystic masses, localized to one ovary, and have an indolent clinical course. Early stage disease has an excellent outcome and Type I tumors cause only 10% of ovarian cancer deaths13. Type I tumors tend to be resistant to chemotherapy and patients with advanced disease have a poor prognosis. Subtypes include low-grade serous, endometrioid, clear cell and mucinous carcinomas. 

1.1.1. Low grade serous carcinomas (LGSC)
LGSCs account for only 3-8% of epithelial ovarian cancers ADDIN EN.CITE 8,14,15. The median age of onset of 43-55 years is lower than that for ovarian cancers overall ADDIN EN.CITE 16, thus this histology is enriched in AYAs. In contrast to other Type I cancers, LGSCs commonly spread beyond the pelvis at diagnosis ADDIN EN.CITE 14,16,17 and Ca125 is usually elevated ADDIN EN.CITE 16,17. Activation of the mitogen-activated protein (MAP) kinase pathway is common in LGSC with mutations in KRAS and BRAF in up to 41% ADDIN EN.CITE 18 and 33%19 cases respectively. LGSC is distinguished from high grade serous carcinomas (HGSC) by wild-type expression of p53 and over-expression of estrogen and progesterone receptors ADDIN EN.CITE 16. LGSC is biologically more indolent than HGSC with a similar PFS of 18 months but longer OS (median 82-99 months) ADDIN EN.CITE 16.

1.1.2. Endometrioid and Clear Cell Carcinomas (CCC)
Endometrioid and clear cell carcinomas (CCC) are associated with endometriosis in 15-30% of cases8, which might partially explain the younger age of onset compared to Type II cancers. Endometrioid cancers can be low or high grade, whereas CCC are always considered to be high grade tumors. Both are characterized by inactivating mutations in ARID1a ADDIN EN.CITE 20  Mutant PTEN is found in 15-20% endometrioid and 10% CCC ADDIN EN.CITE 21, while activation of PIK3CA occurs in 20% of both subtypes22. The common origin of endometrioid cancers and CCC in endometriosis explains their shared molecular characteristics and interestingly, ARID1A, PIK3CA and KRAS have been identified in benign endometriotic lesions ADDIN EN.CITE 23. Endometrioid ovarian cancer, like endometrioid endometrial cancer, harbors microsatellite instability in up to 20% cases13 with loss of expression of one or more of MLH1, MSH2, MSH6 and PSM2. These genes are commonly mutated in familial Lynch Syndrome, which is also associated with ovarian cancer, most commonly the endometrioid subtype. Twenty-five percent of Lynch-associated ovarian cancers are diagnosed below age 40 and usually have early stage disease and favorable survival ADDIN EN.CITE 24. 

1.1.3. Mucinous Tumors
These rare, chemotherapy-resistant tumors account for 3.6% epithelial ovarian cancers8. They affect younger patients (median age 5725) and occasionally occur in AYAs. The origin of these tumors is contentious. They could arise as somatic transformation from ovarian teratomas13 but the most common diagnostic challenge is to differentiate from metastatic tumors of the gastro-intestinal tract. Colonoscopy and gastroscopy is usually recommended. 

2. NON-EPITHELIAL CANCERS
2.1 Ovarian Germ Cell Tumors
Ovarian germ cell tumors (OGCTs) are rare, accounting for just 2-3% of ovarian tumors ADDIN EN.CITE 7 but their incidence is higher AYA patients compared to other age groups26. After age 20, their incidence declines as epithelial cancer increases steadily for the remainder of adult life (Fig.2). OGCTs are divided into different histologies. Mature Teratomas (MT) are benign but may rarely undergo transformation to somatic malignancies such as squamous cell cancer. Immature teratomas (IT) are graded (1-3) according to the amount of neuro-epithelial differentiation. Primitive OGCT subtypes include: dysgerminoma (Dys), yolk sac tumor (YST), embryonal carcinoma (EC) and choriocarcinoma. Alpha-fetoprotein (AFP) is useful in confirming diagnosis of YST, while dysgerminomas and choriocarcinomas may secrete βHCG and LDH. In contrast to epithelial ovarian cancers, OGCTs originate in the ovary. Most patients present with localized disease and Ca125 is not a useful biomarker.  Prognosis is excellent with overall survival rates exceeding 90%. 

2.2 Sex Cord Stromal Tumors (SCST) and Small Cell Tumors
These uncommon ovarian cancers (1-3%) ADDIN EN.CITE 7 generally present before the age of 30 ADDIN EN.CITE 27 and represent 10% of all ovarian tumors in childhood and adolescence28. SCST are usually localized to the ovary, where they can form large masses at risk of torsion and rupture ADDIN EN.CITE 27. SCSTs can produce estradiol or testosterone giving rise to clinical signs such as hirsuitism, virilization, menstrual abnormalities and early puberty29. Their clinical course is generally indolent but occasionally they pursue a more aggressive course with repeated recurrences. The most common pathological subtypes are granulosa cell tumors (GrCTs) and Sertoli-Leydig tumor (SLCT). A rare, indolent subtype known as SCST with annular tubules is associated with STK11 mutations in Peutz-Jeghers Syndrome ADDIN EN.CITE 27. SEER data demonstrate that SCSTs are significantly more common in black compared to white women (0.18 vs 0.35 per 100,000 person years, relative risk, 0.53; 95%CI, 0.42-0.67) ADDIN EN.CITE 27,30.

2.2.1. Granulosa cell tumors (GrCTs)
Adult type GrCTs have a median age of onset of 50-55 years ADDIN EN.CITE 27,31 and commonly present with signs of hyper-estrogenism. FOXL2 has been identified as a driver gene and is useful in confirming the diagnosis ADDIN EN.CITE 32. The prognosis of adult GrCTs relates strongly to stage, ranging from 10 year survival rate of over 90% (Stage I) to 57% (Stage IV)33. Late recurrence with a protracted clinical course is frequently observed. Inhibin B and anti-mullerian hormone have clinical utility in detecting relapse after primary treatment. 

In contrast, juvenile GrCTs are rare, comprising only 5% of all granulosa cell tumors ADDIN EN.CITE 31 and nearly always occur in children (85% cases). Approximately 80% patients have precocious puberty at presentation ADDIN EN.CITE 31. FOXL2 mutations are rarely detected ADDIN EN.CITE 32 but in one series, AKT1 mutations were observed in 63% cases  ADDIN EN.CITE 34. Although prognosis is generally better than for adult-type GrCT, late stage disease is associated with an aggressive clinical course and long term survival is rare ADDIN EN.CITE 31.

2.2.2. Sertoli Leydig Tumors (SLCT)
SLCTs account for less than 0.5% ovarian sex-cord stromal tumors overall ADDIN EN.CITE 31 but up to 20% in children ADDIN EN.CITE 27. Lower patient age correlates with less well-differentiated disease and a worse prognosis ADDIN EN.CITE 31. SLCTs are associated with hereditary mutations in DICER1 (60%) ADDIN EN.CITE 35.  Somatic and germline loss-of-function mutations are associated with a syndrome including pleural pulmonary blastomas (PPB), renal carcinomas, goiter, thyroid carcinoma and pituitary blastoma ADDIN EN.CITE 27. Familial screening has enabled early diagnosis and improved outcomes for these rare childhood cancers ADDIN EN.CITE 36.   

2.2.3. Small Cell of the Ovary
Small cell carcinomas account for <0.1% of all ovarian cancers ADDIN EN.CITE 31 and can be either hypercalcaemic (SCCOHT) or neuroendocrine. Both subtypes have a poor prognosis. The neuroendocrine type, also known as pulmonary type, pathologically resembles small cell lung cancer. Patients with SCCOHT present in the third decade with rapidly enlarging unilateral masses and paraneoplastic hypercalcaemia. They have recently been found to be associated with somatic and germline mutations in SMARCA4 (90% patients) ADDIN EN.CITE 37. The gene product, BRG1 is a chromatin remodeling protein and potentially amenable to future drug development. Unfortunately, the median survival in advanced disease is only 6 months ADDIN EN.CITE 38. Since outcomes are better in early stage disease, screening of affected family members is a priority.

Treatment (Fig.5A and Fig.5B)
1. Type II Epithelial Cancers
Standard surgical treatment for adult women with Type II epithelial ovarian cancer includes debulking surgery with total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and removal of all visible residual disease. Complete surgical debulking to no macroscopic residual disease is associated with improved survival at all FIGO stages ADDIN EN.CITE 39 and is the desired outcome for all adult patients. Treatment usually includes six cycles of carboplatin and paclitaxel chemotherapy, either as six adjuvant cycles or divided as neo-adjuvant and adjuvant therapy ADDIN EN.CITE 40,41. Concurrent and maintenance treatment with the vascular endothelial growth factor inhibitory antibody, bevacizumab, has been shown to improve progression-free (PFS) and overall survival (OS) in high risk patients, defined as those with stage IV cancer or women with residual disease remaining after surgery ADDIN EN.CITE 42,43.  

Despite aggressive treatment, relapse occurs in over 85% cases. Treatment for women relapsing more than 6 months from their last chemotherapy, defined as platinum-sensitive, is with platinum-containing, doublet chemotherapy regimens ADDIN EN.CITE 44,45. Platinum-resistant disease, defined as relapse within six months, is usually treated with non-platinum-based chemotherapy regimens or with experimental agents on clinical trials. Clinical response to chemotherapy decreases with sequential treatments and in platinum-resistant disease, the maximal response rate is only 30-40% with a median overall survival of 12 months ADDIN EN.CITE 46,47. 

2. Type I Epithelial Cancers:
Despite their known resistance to platinum-containing chemotherapy, treatment of Type I cancers, is still based on the more common Type II tumors, with debulking surgery and platinum-containing chemotherapy. Mucinous tumors are often treated with regimens more commonly used to treat gastrointestinal malignancies, such as FOLFOX, although response to these agents is poor and clinical trial data is lacking ADDIN EN.CITE 48. 

LGSCs respond poorly to chemotherapy ADDIN EN.CITE 15,49,50 and chemotherapy is increasingly avoided altogether in this subtype. LGSCs commonly express estrogen (ER) and progesterone receptors (PR). A retrospective study has shown benefit of anti-estrogens in the adjuvant setting ADDIN EN.CITE 51. Another case series demonstrated response to bevacizumab ADDIN EN.CITE 52.  Currently, no consensus exists on when to use anti-angiogenic and anti-estrogen therapies. Clinical trials are under development. The combined lack of chemotherapy response and need for hormonal suppression provides a rationale for aggressive surgery with the aim of achieving complete debulking rates upfront. This clearly has implications for AYA patients, in whom this rare and indolent histology is more common.

3. Germ Cell Cancers
Fertility-sparing surgery is the standard of care ADDIN EN.CITE 53-55. National Comprehensive Cancer Network53 and European Society for Medical Oncology56 guidelines recommend adjuvant chemotherapy with Bleomycin, Etoposide and Cisplatin (BEP). BEP causes significant long-term toxicities57 and increasingly oncologists are exploring strategies to reduce late effects for young patients with a high likelihood of cure. One strategy is active post-operative surveillance for stage I disease. In a trial of 25 girls up to age 16 (mean 12 years) with stage I disease, 50% were spared chemotherapy and four year OS was 96% ADDIN EN.CITE 58. ESMO guidelines now allow surveillance of “properly staged” IA-C dysgerminoma; stage IA, Gd1-3 IT and IA/B YST56. There is ongoing debate about the efficacy of chemotherapy in IT and many now advocate exclusively surgical management of this subtype. This is supported by a retrospective analysis of IT patients treated in pediatric (COG: Children’s Oncology Group and CCLG: Children’s Cancer and Leukaemia Group) and adult (GOG: Gynecologic Oncology Group) clinical trials, which demonstrated slightly lower survival in adult compared to pediatric patients (93% vs 99%) despite much higher administration of adjuvant chemotherapy (81/81 adult patients vs 8/98 children) ADDIN EN.CITE 59. 

4. Sex-cord stromal and small cell cancers
Surgery is the primary treatment of these rare tumors. In the better prognosis SCST, fertility-sparing surgery is usual, although frequent recurrence of adult GrCTs often requires repeated surgical intervention. There is evidence for hormonal therapies in adult granulosa cell tumors ADDIN EN.CITE 60. SLCT are more aggressive and are often treated with chemotherapy61. The small cell cancers, and higher risk and recurrent, inoperable SCSTs are treated with either BEP or carboplatin/paclitaxel62. The neuroendocrine type may be treated with carboplatin and etoposide as per small cell carcinoma of the lung ADDIN EN.CITE 63. Emerging evidence suggests a role for immunotherapy in the SCCOHT64, and checkpoint inhibitors have been proposed for neuroendocrine tumors based on their efficacy in small cell carcinoma of the lung ADDIN EN.CITE 31. Autologous stem cell transplants are recommended for SCCOHT in recent ESMO guidlines56.

Specific treatment considerations in AYA patients with ovarian malignancies:
1. ACCESS TO CARE:
Access to care is a potential barrier for AYA patients, particularly in countries where younger people may not have primary care physicians and often lack an understanding of the most appropriate specialist. In the US, there is a concern that AYAs are under-insured, which may lead to delays in referral and treatment. A recent US study of AYA patients with ovarian germ cell tumors found that patients with lower socio-economic status and education presented with higher stage disease, perhaps reflecting diagnostic delay ADDIN EN.CITE 65. However, there were no differences in time to start treatment, extent of surgery and chemotherapy and encouragingly, socioeconomic status did not influence stage-specific survival.

2. GENETIC RISK
Hereditary genetic mutations are identified in approximately 20% of women with ovarian cancer66 and genetic testing is increasingly available for specific, cancer-associated germline mutations. In AYA patients this often occurs following a cancer diagnosis or after diagnosis of a family member. When a mutation increases the risk of cancer in adult life, it may be ethical to wait until the patient is 18 years old and can consent, rather than testing during childhood. Access to genetic counselling is essential. AYA patients from cancer families are often aware of their risk and may have experienced loss of a parent, often their mother, at a young age67. Increasing genetic knowledge among healthcare providers needs to be matched by an understanding of the complex life trajectories in affected AYA patients. 

3. SURGERY:
Surgery has a proven role in the management of adult epithelial ovarian cancer and since most women will be post-menopausal there are few additional side effects associated with removal of gynecological organs. In younger women, induction of early menopause following surgery, as cancer treatment or as prophylaxis, is associated with permanent infertility and significant physical and psychological morbidity. Physical disfigurement can be a source of considerable additional distress. Fertility-sparing surgery should be considered and in these cases a laparoscopic approach may be preferred. 

4. FERTILITY
The American Society for Reproductive Medicine (ASRM)68 and the American Society for Clinical Oncology ADDIN EN.CITE 69 have published fertility preservation practice guidelines for cancer patients receiving gonadotoxic therapy. Guidelines cover the need to anticipate and discuss fertility preservation options and to refer patients as early as possible to reproductive specialists. Evidence suggests this information is important to cancer patients but may be overshadowed by fears about their underlying cancer and reluctance to delay treatment. Oncologists are motivated to discuss fertility, but barriers for referral persist.  In a review of providers to adolescent cancer patients, 46% stated that they refer male cancer patients to a fertility specialist more than 50% of the time.  For females, this figure was only 12% ADDIN EN.CITE 70. There was also a lack of knowledge on fertility options such as emergency in vitro fertilization (IVF) in 36% and intracytoplasmic sperm injection (ICSI) in 55% of healthcare providers ADDIN EN.CITE 70.

Assisted reproductive technologies exist for female patients, although funding and availability vary widely. For adult women, the most well-known is embryo cryopreservation following in vitro fertilization. Mature oocyte preservation is no longer considered experimental71 and is an option. This technique has been improved by the process of vitrification, in which the oocyte is rapidly frozen using liquid nitrogen. Early results in women under 37 years suggest that the pregnancy success rate is similar to that using fresh oocytes72. The major limitation of these techniques is the time required for ovarian stimulation (9-12 days) together with the need to align treatment with a menstrual cycle73. A small series using a “random-start protocol” has shown promise ADDIN EN.CITE 74. 

Girls and adolescents have good fertility outcomes following treatment for ovarian cancers that are most common in the AYA ages. In one series of 40 patients (median age 22) treated with fertility-sparing surgery and BEP chemotherapy for ovarian YST, normal menstrual function was retained in 97% and pregnancies were reported in 75% of patients who attempted conception ADDIN EN.CITE 75. For the small number of younger patients who require more aggressive surgery, options for preserving fertility are limited. Oocyte preservation is only possible after puberty and requires patient assent and parent consent ADDIN EN.CITE 69. Parents are often unsure about how to advise their children and guidance documents have now been created by both the American Academy of Pediatrics76 and the ASRM77.  Ovarian tissue preservation remains experimental with no live births yet reported ADDIN EN.CITE 69. Although children often find it difficult to understand future fertility implications of cancer treatment, studies show that adult survivors would have valued greater information ADDIN EN.CITE 69. Finally, “third party reproduction”, in which eggs, sperm, embryos or a uterus are donated by a third party, remains a future option for patients who could not have fertility-sparing surgery73.
  
5. IATROGENIC MENOPAUSE
Ovarian cancer treatment often causes early menopause and symptoms are frequently more severe than in natural menopause. Adverse effects on cardiovascular and bone health are significant in young women and need particular attention in those with curable cancers. Data regarding hormone replacement therapy for these women are scarce and clinical decision making is weighted according to histological disease subtype, hormone receptor expression, patient age and predicted outcome. 

Surgically-induced early menopause increases the risk of diverse morbidities including cardiac events, osteoporosis and impaired mental health. All require careful management but discussion of these complex issues is beyond the scope of his review. The most commonly reported menopausal symptoms are vasomotor78 and, when HRT is contra-indicated, anti-depressant drugs, venlafaxine and paroxetine ADDIN EN.CITE 79,80 and the anti-convulsants gabapentin and pregabablin have shown benefit compared to placebo in randomized trials ADDIN EN.CITE 79,80. Vaginal dryness and dyspareunia and can be treated with vaginal lubricants79 and in some cases low-dose vaginal estrogen creams79. Acupuncture, mindfulness training, yoga, relaxation therapy, cognitive behavioral therapy and hypnosis are all used for a variety of menopausal symptoms. Data on these measures are limited ADDIN EN.CITE 79,80. These issues can be difficult for young women to discuss and should be systemically addressed during follow-up visits.

Conclusions:
A diverse range of malignant diseases can occur in the ovary, the frequency of which changes throughout life. Although OGCTs are the most common histology in the AYA age group, the variety of malignant ovarian histologies contrasts sharply with the overwhelming predominance of GCT in male AYA patients. Unfortunately, epithelial ovarian cancer subtypes do not have favorable outcomes as seen in OGCT and fertility-sparing surgery is often not possible. Thus, ovarian cancer treatment creates unique toxicity concerns in young women. The management of future fertility requires careful forward planning while iatrogenic menopause needs lifelong treatment to minimize associated morbidity and chronic complications. Therapeutic approaches for all ovarian histologies are changing rapidly as our molecular understanding gathers pace. It is imperative that AYA patients are recruited to the growing portfolio of clinical trials to improve survival and reduce chronic toxicities in these young women.
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